and that is what i find so telling since Feb - Mar 2018

New Post Public Reply Private Reply Replies (0) Message Board
4kids petemantx #45309
354
and that is what i find so telling since Feb - Mar 2018

imo IPIX (even with known events of 2014/2015) has always had the *liquidity* that both NR provide/s and traders provide

that is .. up until this past year

but it's now the almost total lack of *liquidity* (imo very evident) that i suspect
has forced NRs' hand in alignment with what mgmt has filed .. that has changed

the gamble in play imo is huge (risk) for NR .. even tho' they can compress IPIX down every day .. until of course they can't

but NR is used to controlling outcomes .. when they *cant* .. it can be EPIC

i too added today .. and have another bid patiently waiting for NRs' predictable patterns

my bid was split in 2 fills (2 MMs' reporting) .. and part of it was bundled into a trade that was mirrored (duplicated) .. 2500 .. i'll post out when i do the tape of trades for today ..

nice post btw

4kids

Am on another close knit board but many there are more traders than investors. As one would imagine, they are going berserk over the rapid drop in price over the last month or so. I answered them below, trying to allay some of their fears and trying to make them realize what they have in an IPIX investment:


Investors know what they own, traders only know what they see on a chart. Investors know what the company has said in regards to when they will announce deals, traders want action today regardless of the process needed to attain large returns (same problem most companies have today in worrying about quarterly returns instead of long term growth and profitability). IPIX was in the .70s a mere month or two ago. What has changed for this rapid drop? Negative news? No. Competitor products being approved that diminishes the chances for our products to succeed? No, just the opposite. Has mgt quit communicating with shareholders due to dire circumstances? No, just the opposite, in talks with BPs as to deals as evidenced by CDAs.

If you don't believe Brilacidin has already established itself as a billion dollar drug that could rival Humira down the line in annual sales, being an antibiotic/anti-inflammatory and a probable large dermatology related success then sell and chase your pennies in other stocks you can trade daily. We know we are but days to a couple of weeks away from Prurisol P2b results that could (and I believe should) result in Prurisol becoming the leading treatment for psoriasis, but if you can't handle the short wait then IPIX is not for you. Biotech doesn't work on a fast track. If you don't believe the hundred Billion $+ reserves of BPs are looking for a pipeline in which to invest and cannot see that IPIX has the most astounding lineup of 3 drugs already thru P2 trials, then IPIX is not for you. If you are jumping with joy at a gain of a price share rise to $3/share and cannot wait a matter of a month or two for a possibility of 10X that then IPIX is not for you. Play your charts, make your pennies, and be happy. Is success guaranteed? No. But look at what is in our favor. 5 trials with no failures and NO SAFETY ISSUES. Does eveyone understand the value in that for a pipeline of drugs that should work in a revenue stream of $100B/ yr? In the realm of biotech that is nearly beyond belief and is worth an immeasurable amount. To put it in perspective, how much revenue a yr is NXO going to get from the camera for iphones and such? Would most be happy w/ $1Billion/yr? Brilacidin has as it's smallest target Oral Mucositis and that alone should reach that level. Add in IBD (Irritable Bowel Disorders) and you get maybe an additional $10-15B, add in dermatology apps and another possible $20B, add in antibiotic uses at another number of Billions, then Prurisol just for psoriasis possible $5-8B/yr and the rest of the anti-immune diseases (there are about 100 of them) many billions and we haven't even mentioned Kevetrin that has achieved being able to energize the pathway to ignite the p53 gene (the Guardian Angel Gene) and the most researched subject in medical history. The top cancer drugs did about $90 billion / yr and K could become a combo drug for all or most of them. I'd say IPIX odds are very high in becoming a very successful company, but if you can't stand some heat sell and get back in after the deals are actually signed. As it is now, though, most sound like they have bought the paid trolls garbage of no science, no mgt, no opportunities, et al and it sickens me to see so many buying their rot. There are very, very few true golden rings to grab in the field of investing. IPIX is one, so obstacles are to be expected and risks taken. That is why there is such a large operation in place to try and undermine them at this point in time , because the shorts know their time of ruling the share price is about to come to an end.

The company's latest PR was about selecting German based EVONIK as the contractor to make our Brilacidin sachets for Oral Mucositis and this will be the exact formulation that we will bring to market. Ergo, we have solved the formulation for the sachet. Who is EVONIK? 38K employees operating in over 100 countries with yearly revenues of about 14B Euros per year. They have a major Investing arm and they will be able to provide IPIX with gels/foams/creams/pills/IV solutions. Could we be discussing a partnership with them so that we two also distribute the OM sachet worldwide and keep this $1B+ revenue stream to ourselves? The revenue stream should actually rise significantly as rather than just for head and neck cancers, this product will be so easy to administer and be so universally effective that all patients being treated with radiation/chemo will be prescribed it as no oncologist will want to get hit with a lawsuit should their patient get OM and they didn't prescribe this easy fix for the problem ever occurring. This is just one of many scenarios that could be playing out. Again, it doesn't happen overnight, but EVONIK doesn't get in bed with companies that they don't see have a good future.

Maybe we don't partner with EVONIK for worldwide distribution, but in negotiating with BPs Leo could sure use this possibility as a leverage point as to why BP better step to the plate with an acceptable offer. We aren't going into these negotiations with an empty pistol. We are negotiating from a position of strength.

I am not trying to say IPIX is a given success, I am only trying to stress why it should be viewed with a different set of eyes than a normal stock which has only millions to hundreds of millions in possible revenues.

Just for those needing a refresher, Dr Bertolino was head of dermatoloy for both Pfizer and Novartis and his contacts and expertise in this field should be of immense value for selling Brilicidin for dermatology applications (Eczema, acne, and Hidradenitis Suppurativa) which have yearly revenues over $40B.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 52

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 21

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 0

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 34

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 54

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading

Top 5 Most Recently Viewed Articles

Duos Technologies Secures $40 Million Offering for Growth

Updated Category News Views 263

Duos Technologies Announces Successful Pricing of Public Offering Duos Technologies Group, Inc. (Nasdaq: DUOT) has successfully priced its public offering of common stock, raising $40 million to expand its operations and address its ambitious revenue goals. Overview of the Offering In a recent announcement, Duos unveiled that it will be offering 6,666,667 shares of its...

Continue Reading
Understanding TELUS Intl's Upcoming Earnings Report

Updated Category News Views 170

TELUS Intl Quarterly Earnings Overview TELUS Intl (TIXT) is preparing to unveil its quarterly earnings report, sparking interest among investors keen on understanding the company's performance and future outlook. As we approach the announcement, anticipation grows regarding the possible results and guidance. Investor Expectations Analysts have set their eyes on TELUS...

Continue Reading
America's Car-Mart Reports Q1 Results and Strategic Focus

Updated Category News Views 70

America's Car-Mart Focuses on Strategic Growth Amid Revenue Declines America's Car-Mart Inc. (NASDAQ: CRMT), a leading automotive retailer in the United States, has recently released its financial results for the first quarter of fiscal 2025. The company reported a revenue decline of 5.2%, primarily due to a decrease in retail units sold. However, America's Car-Mart is...

Continue Reading
Kayne Anderson Energy Infrastructure Fund Declares New Share Distribution

Updated Category News Views 108

Distribution Announcement from Kayne Anderson Energy Infrastructure Fund Kayne Anderson Energy Infrastructure Fund, Inc. has officially announced a monthly distribution of $0.08 per share. This upcoming payment is scheduled for common stockholders and highlights the fund's commitment to providing returns to its investors. Details of the Monthly Distribution The...

Continue Reading
Giftify, Inc. Celebrates Revenue Growth and Strategic Advancements

Updated Category News Views 249

Revenue Highlights and Profit Growth Giftify, Inc. (NASDAQ: GIFT), a major player in the incentives and rewards industry, reported impressive financial results for the first quarter. The company's revenue soared by 3.5%, reaching $22.3 million, demonstrating its resilience in a competitive market. Moreover, the company's gross profit increased by 10%, now standing at $3.6...

Continue Reading